Detection and Monitoring of Gastrointestinal Cancer and Cancer Recurrence by laser-based infrared Molecular Fingerprinting

Detection and Monitoring of Gastrointestinal Cancer and Cancer Recurrence by laser-based infrared Molecular Fingerprinting - L4L GIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028668

Enrollment

120

Registered

2022-12-27

Start date

2023-02-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25 C22.1 C22.0 C18

Interventions

Group 1: Study participants with liver cancer, colorectal cancer, cholangiocellular adenocarcinoma and pancreatic cancer are informed in detail about the course, risks, and benefits of the study. I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Adults > 18 years who are able to consent to this study • Patient has consented to this study • Resectable gastrointestinal tumor such as liver cancer, colorectal cancer, cholangiocellular adenocarcinoma and pancreatic cancer • In the case of HCC and/or liver cirrhosis Child-Pugh class A or B. Only patients with Child-Pugh index class B of not more than 7 will be included • Life expectancy of 12 weeks or more

Exclusion criteria

Exclusion criteria: • Patients unable to consent • Pregnant and breastfeeding women • Tumor or tumortherapy within the last 2 years • Multiple cancers • Renal failure requiring hemo- or peritoneal dialysis. • In the case of HCC and/or liver cirrhosis Child-Pugh index class B in combination with more than slight ascites or hepatic encephalopathy > Grade I

Design outcomes

Primary

Measure	Time frame
Area underneath the receiver operating characteristic function (AUC) of spectral features (GMFs) for discriminating blood samples of patients with confirmed liver cancer, colorectal cancer, cholangiocellular adenocarcinoma and pancreatic cancer. Spectral features are derived using laser-based infrared spectrosopy.	—

Secondary

Measure	Time frame
• Proteomic profiles from mass spectrometry of blood samples of patients with confirmed liver cancer, colorectal cancer, cholangiocellular adenocarcinoma and pancreatic cancer • Routine clinical data, including medical imaging data and currently used biomarkers, of patients with confirmed liver cancer, colorectal cancer, cholangiocellular adenocarcinoma and pancreatic cancer.	—

Countries

Germany

Contacts

Public ContactJacqueline Hermann

Klinikum der Universität München

jacqueline.hermann@med.uni-muenchen.de0049 174 3045 058

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026